These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
426 related articles for article (PubMed ID: 21283108)
1. Emerging therapeutic opportunities for skeletal restoration. Kawai M; Mödder UI; Khosla S; Rosen CJ Nat Rev Drug Discov; 2011 Feb; 10(2):141-56. PubMed ID: 21283108 [TBL] [Abstract][Full Text] [Related]
2. [Once-weekly teriparatide treatment on osteoporosis]. Nakano T Clin Calcium; 2014 Jan; 24(1):100-5. PubMed ID: 24369286 [TBL] [Abstract][Full Text] [Related]
3. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Stevenson M; Jones ML; De Nigris E; Brewer N; Davis S; Oakley J Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857 [TBL] [Abstract][Full Text] [Related]
4. [Up-to-date treatments for osteoporosis]. Bors K Orv Hetil; 2006 Feb; 147(7):301-6. PubMed ID: 17489157 [TBL] [Abstract][Full Text] [Related]
5. Treatment of osteoporosis with parathyroid hormone and teriparatide. Pleiner-Duxneuner J; Zwettler E; Paschalis E; Roschger P; Nell-Duxneuner V; Klaushofer K Calcif Tissue Int; 2009 Mar; 84(3):159-70. PubMed ID: 19189037 [TBL] [Abstract][Full Text] [Related]
6. Teriparatide in the treatment of osteoporosis. Stroup J; Kane MP; Abu-Baker AM Am J Health Syst Pharm; 2008 Mar; 65(6):532-9. PubMed ID: 18319498 [TBL] [Abstract][Full Text] [Related]
7. Abaloparatide: A new pharmacological option for osteoporosis. Sleeman A; Clements JN Am J Health Syst Pharm; 2019 Jan; 76(3):130-135. PubMed ID: 30689744 [TBL] [Abstract][Full Text] [Related]
9. Bisphosphonates for osteoporosis in people with cystic fibrosis. Conwell LS; Chang AB Cochrane Database Syst Rev; 2012 Apr; (4):CD002010. PubMed ID: 22513903 [TBL] [Abstract][Full Text] [Related]
10. Bisphosphonates for osteoporosis in people with cystic fibrosis. Conwell LS; Chang AB Cochrane Database Syst Rev; 2014 Mar; 2014(3):CD002010. PubMed ID: 24627308 [TBL] [Abstract][Full Text] [Related]
11. Anabolic skeletal therapy for osteoporosis. Girotra M; Rubin MR; Bilezikian JP Arq Bras Endocrinol Metabol; 2006 Aug; 50(4):745-54. PubMed ID: 17117299 [TBL] [Abstract][Full Text] [Related]
12. Summary of AHRQ's comparative effectiveness review of treatment to prevent fractures in men and women with low bone density or osteoporosis: update of the 2007 report. Levis S; Theodore G J Manag Care Pharm; 2012 May; 18(4 Suppl B):S1-15; discussion S13. PubMed ID: 22716221 [TBL] [Abstract][Full Text] [Related]
13. Management of postmenopausal osteoporosis and the prevention of fractures. Gambacciani M; Levancini M Panminerva Med; 2014 Jun; 56(2):115-31. PubMed ID: 24942322 [TBL] [Abstract][Full Text] [Related]
14. Bone regeneration in osteoporosis: opportunities and challenges. Patel D; Wairkar S Drug Deliv Transl Res; 2023 Feb; 13(2):419-432. PubMed ID: 35994158 [TBL] [Abstract][Full Text] [Related]
15. Antifracture efficacy of currently available therapies for postmenopausal osteoporosis. Reginster JY Drugs; 2011 Jan; 71(1):65-78. PubMed ID: 21175240 [TBL] [Abstract][Full Text] [Related]
16. Prescription drug therapies for prevention and treatment of postmenopausal osteoporosis. O'Connell MB J Manag Care Pharm; 2006 Jul; 12(6 Suppl A):S10-9; quiz S26-8. PubMed ID: 17269853 [TBL] [Abstract][Full Text] [Related]
17. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. Wensel TM; Iranikhah MM; Wilborn TW Pharmacotherapy; 2011 May; 31(5):510-23. PubMed ID: 21923432 [TBL] [Abstract][Full Text] [Related]
18. Teriparatide (rhPTH 1-34) for the treatment of osteoporosis. Ebeling PR; Russell RG Int J Clin Pract; 2003 Oct; 57(8):710-8. PubMed ID: 14627183 [TBL] [Abstract][Full Text] [Related]
19. Treatment of osteoporosis with Teriparatide rhPTH(1-34). San Martin J J Musculoskelet Neuronal Interact; 2004 Dec; 4(4):406. PubMed ID: 15758281 [No Abstract] [Full Text] [Related]